Absence of CHEK2*1100delC mutation in families with hereditary breast cancer in North America

Maria D. Iniesta, Michael Gorin, Ling Chen Chien, Samantha M. Thomas, Kara J. Milliron, Julie A. Douglas, Sofia D. Merajver

Research output: Contribution to journalArticle

Abstract

The CHEK2*1100delC mutation has been reported to confer a twofold increased risk of breast cancer among carriers. The frequency of the mutation varies among populations. The highest frequency has been described in Northern and Eastern European countries; the frequency may be much lower in North America. In this study, our aim was to determine the frequency of CHEK2*1100delC in members of breast cancer families who tested negative for a deleterious mutation in BRCA1/2 at the University of Michigan Comprehensive Cancer Center. We genotyped 102 members from 90 families for CHEK2*1100delC. Most of these families had several cases of breast cancer or ovarian cancer (or both), as well as multiple members with other cancer types in a single lineage. No CHEK2*1100delC mutations were detected in any of the 102 individuals, including 51 women diagnosed with breast cancer at an early age (<45 years), 8 women with bilateral breast cancer, 3 men with breast cancer, and 8 women with ovarian cancer. Our data are consistent with the reported very low frequency of CHEK2*1100delC mutations in North American populations (compared with Northern Europe), rendering CHEK2*1100delC such an unlikely culprit in BRCA1/2 negative families that routine testing of these families appears unwarranted.

Original languageEnglish (US)
Pages (from-to)136-140
Number of pages5
JournalCancer Genetics and Cytogenetics
Volume202
Issue number2
DOIs
StatePublished - Oct 1 2010
Externally publishedYes

Fingerprint

North America
Breast Neoplasms
Mutation
Ovarian Neoplasms
Mutation Rate
Population
Neoplasms

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Iniesta, M. D., Gorin, M., Chien, L. C., Thomas, S. M., Milliron, K. J., Douglas, J. A., & Merajver, S. D. (2010). Absence of CHEK2*1100delC mutation in families with hereditary breast cancer in North America. Cancer Genetics and Cytogenetics, 202(2), 136-140. https://doi.org/10.1016/j.cancergencyto.2010.07.124

Absence of CHEK2*1100delC mutation in families with hereditary breast cancer in North America. / Iniesta, Maria D.; Gorin, Michael; Chien, Ling Chen; Thomas, Samantha M.; Milliron, Kara J.; Douglas, Julie A.; Merajver, Sofia D.

In: Cancer Genetics and Cytogenetics, Vol. 202, No. 2, 01.10.2010, p. 136-140.

Research output: Contribution to journalArticle

Iniesta, Maria D. ; Gorin, Michael ; Chien, Ling Chen ; Thomas, Samantha M. ; Milliron, Kara J. ; Douglas, Julie A. ; Merajver, Sofia D. / Absence of CHEK2*1100delC mutation in families with hereditary breast cancer in North America. In: Cancer Genetics and Cytogenetics. 2010 ; Vol. 202, No. 2. pp. 136-140.
@article{0ed38bbf931c4bda8be1905e73b0a428,
title = "Absence of CHEK2*1100delC mutation in families with hereditary breast cancer in North America",
abstract = "The CHEK2*1100delC mutation has been reported to confer a twofold increased risk of breast cancer among carriers. The frequency of the mutation varies among populations. The highest frequency has been described in Northern and Eastern European countries; the frequency may be much lower in North America. In this study, our aim was to determine the frequency of CHEK2*1100delC in members of breast cancer families who tested negative for a deleterious mutation in BRCA1/2 at the University of Michigan Comprehensive Cancer Center. We genotyped 102 members from 90 families for CHEK2*1100delC. Most of these families had several cases of breast cancer or ovarian cancer (or both), as well as multiple members with other cancer types in a single lineage. No CHEK2*1100delC mutations were detected in any of the 102 individuals, including 51 women diagnosed with breast cancer at an early age (<45 years), 8 women with bilateral breast cancer, 3 men with breast cancer, and 8 women with ovarian cancer. Our data are consistent with the reported very low frequency of CHEK2*1100delC mutations in North American populations (compared with Northern Europe), rendering CHEK2*1100delC such an unlikely culprit in BRCA1/2 negative families that routine testing of these families appears unwarranted.",
author = "Iniesta, {Maria D.} and Michael Gorin and Chien, {Ling Chen} and Thomas, {Samantha M.} and Milliron, {Kara J.} and Douglas, {Julie A.} and Merajver, {Sofia D.}",
year = "2010",
month = "10",
day = "1",
doi = "10.1016/j.cancergencyto.2010.07.124",
language = "English (US)",
volume = "202",
pages = "136--140",
journal = "Cancer Genetics and Cytogenetics",
issn = "0165-4608",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Absence of CHEK2*1100delC mutation in families with hereditary breast cancer in North America

AU - Iniesta, Maria D.

AU - Gorin, Michael

AU - Chien, Ling Chen

AU - Thomas, Samantha M.

AU - Milliron, Kara J.

AU - Douglas, Julie A.

AU - Merajver, Sofia D.

PY - 2010/10/1

Y1 - 2010/10/1

N2 - The CHEK2*1100delC mutation has been reported to confer a twofold increased risk of breast cancer among carriers. The frequency of the mutation varies among populations. The highest frequency has been described in Northern and Eastern European countries; the frequency may be much lower in North America. In this study, our aim was to determine the frequency of CHEK2*1100delC in members of breast cancer families who tested negative for a deleterious mutation in BRCA1/2 at the University of Michigan Comprehensive Cancer Center. We genotyped 102 members from 90 families for CHEK2*1100delC. Most of these families had several cases of breast cancer or ovarian cancer (or both), as well as multiple members with other cancer types in a single lineage. No CHEK2*1100delC mutations were detected in any of the 102 individuals, including 51 women diagnosed with breast cancer at an early age (<45 years), 8 women with bilateral breast cancer, 3 men with breast cancer, and 8 women with ovarian cancer. Our data are consistent with the reported very low frequency of CHEK2*1100delC mutations in North American populations (compared with Northern Europe), rendering CHEK2*1100delC such an unlikely culprit in BRCA1/2 negative families that routine testing of these families appears unwarranted.

AB - The CHEK2*1100delC mutation has been reported to confer a twofold increased risk of breast cancer among carriers. The frequency of the mutation varies among populations. The highest frequency has been described in Northern and Eastern European countries; the frequency may be much lower in North America. In this study, our aim was to determine the frequency of CHEK2*1100delC in members of breast cancer families who tested negative for a deleterious mutation in BRCA1/2 at the University of Michigan Comprehensive Cancer Center. We genotyped 102 members from 90 families for CHEK2*1100delC. Most of these families had several cases of breast cancer or ovarian cancer (or both), as well as multiple members with other cancer types in a single lineage. No CHEK2*1100delC mutations were detected in any of the 102 individuals, including 51 women diagnosed with breast cancer at an early age (<45 years), 8 women with bilateral breast cancer, 3 men with breast cancer, and 8 women with ovarian cancer. Our data are consistent with the reported very low frequency of CHEK2*1100delC mutations in North American populations (compared with Northern Europe), rendering CHEK2*1100delC such an unlikely culprit in BRCA1/2 negative families that routine testing of these families appears unwarranted.

UR - http://www.scopus.com/inward/record.url?scp=77957095631&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957095631&partnerID=8YFLogxK

U2 - 10.1016/j.cancergencyto.2010.07.124

DO - 10.1016/j.cancergencyto.2010.07.124

M3 - Article

VL - 202

SP - 136

EP - 140

JO - Cancer Genetics and Cytogenetics

JF - Cancer Genetics and Cytogenetics

SN - 0165-4608

IS - 2

ER -